A team of UK rheumatologists has urged clinicians to not delay treatment with methotrexate in rheumatoid arthritis because of fears over lung injury. In fact, use of methotrexate in a treat-to-target approach in patients with progressive disease may prevent the development of interstitial lung disease (ILD) developing, they conclude. Dr Elena Nikiphorou, a clinical researcher ...
New thinking needed on methotrexate and lung disease risk: expert
By Emma Wilkinson
13 Nov 2019